|
2021 Journal Article Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparumMcCarthy, James S., Abd-Rahman, Azrin N., Collins, Katharine A., Marquart, Louise, Griffin, Paul, Kummel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J. Prakash and Gandhi, Preetam (2021). Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 65 (2) e01423-20. doi: 10.1128/aac.01423-20 |
|
2020 Journal Article Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccineKeech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie and Glenn, Gregory M. (2020). Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of Medicine, 383 (24), 2320-2332. doi: 10.1056/NEJMoa2026920 |
|
2020 Journal Article A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather, Cox, Kara S., Spellman, Daniel S., Winstead, Colleen J., Smolenov, Igor, Lai, Eseng, Zaks, Tal, Espeseth, Amy S. and Panther, Lori (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 17 (5), 1-14. doi: 10.1080/21645515.2020.1829899 |
|
2020 Journal Article Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO studyHenderson, A., Paterson, D. L., Chatfield, M. D., Tambyah, P. A., Lye, D. C., De, P. P., Lin, R. T. P., Chew, K. L., Yin, M., Lee, T. H., Yilmaz, M., Cakmak, R., Alenazi, T. H., Arabi, Y. M., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S. S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D. F. M., Runnegar, N. J., Miyakis, S., Walls, G., AI Khamis, M., Zikri, A. ... For the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2020). Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clinical Infectious Diseases, 73 (11), e3842-e3850. doi: 10.1093/cid/ciaa1479 |
|
2020 Journal Article Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trialLickliter, Jason, Kanceva, Radmila, Vincent, Emmanuelle, Schueler, Armin, Harrison-Moench, Eleanor, Yue, Corinne Seng, Stahl, Michael, Ullmann, Martin, Ghori, Vishal and Griffin, Paul (2020). Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trial. Clinical Therapeutics, 42 (8), 1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020 |
|
2020 Journal Article Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infectionCollins, Katharine A., Abd-Rahman, Azrin N., Marquart, Louise, Ballard, Emma, Gobeau, Nathalie, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J. and McCarthy, James S. (2020). Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infection. The Journal of Infectious Diseases, 225 (6), 1062-1069. doi: 10.1093/infdis/jiaa287 |
|
2020 Journal Article Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 studyPlayford, Elliott Geoffrey, Munro, Trent, Mahler, Stephen M., Elliott, Suzanne, Gerometta, Michael, Hoger, Kym L., Jones, Martina L., Griffin, Paul, Lynch, Kathleen D., Carroll, Heidi, El Saadi, Debra, Gilmour, Margaret E., Hughes, Benjamin, Hughes, Karen, Huang, Edwin, de Bakker, Christopher, Klein, Reuben, Scher, Mark G., Smith, Ina L., Wang, Lin-Fa, Lambert, Stephen B., Dimitrov, Dimiter S., Gray, Peter P. and Broder, Christopher C. (2020). Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. The Lancet Infectious Diseases, 20 (4), 445-454. doi: 10.1016/S1473-3099(19)30634-6 |
|
2020 Journal Article A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteersMcCarthy, James S., Rückle, Thomas, Elliott, Suzanne L., Ballard, Emma, Collins, Katharine A., Marquart, Louise, Griffin, Paul, Chalon, Stephan and Möhrle, Jörg J. (2020). A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers. Antimicrobial Agents and Chemotherapy, 64 (1) e01371-19, e01371-19. doi: 10.1128/AAC.01371-19 |
|
2019 Journal Article Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trialChandra, Janin, Woo, Wai-Ping, Dutton, Julie L., Xu, Yan, Li, Bo, Kinrade, Sally, Druce, Julian, Finlayson, Neil, Griffin, Paul, Laing, Kerry J., Koelle, David M. and Frazer, Ian H. (2019). Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trial. PLoS One, 14 (12) e0226320, 1-20. doi: 10.1371/journal.pone.0226320 |
|
2019 Conference Publication Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trialLickliter, Jason D., Griffin, Paul, Vincent, Emmanuelle, Schuler, Armin, Harrison-Moench, Eleanor, Stahl, Michael, El Bawab, Samer, Kanceva, Radmila and Gascon, Pere (2019). Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31May - 4 June, 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.e14514 |
|
2019 Conference Publication RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous AdministrationCollins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p5.2-079 |
|
2019 Conference Publication RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous AdministrationCollins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. 71st Annual Meeting of the American Academy of Neurology (AAN), Philadelphia, PA, United States, 4-10 May, 2019. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2019 Journal Article DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparumCollins, Katharine A., Rueckle, Thomas, Elliott, Suzanne, Marquart, Louise, Ballard, Emma, Chalon, Stephan, Griffin, Paul, Moehrle, Joern J. and McCarthy, James S. (2019). DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 63 (4) e01837-18. doi: 10.1128/AAC.01837-18 |
|
2019 Journal Article Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trialsManton, Kerry J., Gauld, Cassandra S., White, Katherine M., Griffin, Paul M. and Elliott, Suzanne L. (2019). Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 9 (1) e024224, e024224. doi: 10.1136/bmjopen-2018-024224 |
|
2018 Journal Article Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trialHarris, Patrick N. A., Tambyah, Paul A., Lye, David C., Mo, Yin, Lee, Tau H., Yilmaz, Mesut, Alenazi, Thamer H., Arabi, Yaseen, Falcone, Marco, Bassetti, Matteo, Righi, Elda, Rogers, Benjamin A., Kanj, Souha, Bhally, Hasan, Iredell, Jon, Mendelson, Marc, Boyles, Tom H., Looke, David, Miyakis, Spiros, Walls, Genevieve, Al Khamis, Mohammed, Zikri, Ahmed, Crowe, Amy, Ingram, Paul, Daneman, Nick, Griffin, Paul, Athan, Eugene, Lorenc, Penelope, Baker, Peter ... MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2018). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA, 320 (10), 984-994. doi: 10.1001/jama.2018.12163 |
|
2018 Journal Article Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trialProietto, Joseph, Malloy, Jaret, Zhuang, Dongliang, Arya, Mark, Cohen, Neale D., de Looze, Ferdinandus J., Gilfillan, Christopher, Griffin, Paul, Hall, Stephen, Nathow, Thomas, Oldfield, Geoffrey S., O'Neal, David N., Roberts, Adam, Stuckey, Bronwyn G. A., Yue, Dennis, Taylor, Kristin and Kim, Dennis (2018). Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia, 61 (9), 1918-1922. doi: 10.1007/s00125-018-4677-0 |
|
2018 Journal Article Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trialSekuloski, Silvana, Batzloff, Michael R., Griffin, Paul, Parsonage, William, Elliott, Suzanne, Hartas, Jon, O'Rourke, Peter, Marquart, Louise, Pandey, Manisha, Rubin, Fran A., Carapetis, Jonathan, McCarthy, James and Good, Michael F. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS One, 13 (7) e0198658, e0198658. doi: 10.1371/journal.pone.0198658 |
|
2018 Journal Article Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)Fernando, Germain J. P., Hickling, Julian, Jayashi Flores, Cesar M., Griffin, Paul, Anderson, Christopher D., Skinner, S. Rachel, Davies, Cristyn, Witham, Katey, Pryor, Melinda, Bodle, Jesse, Rockman, Steve, Frazer, Ian H. and Forster, Angus H. (2018). Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine, 36 (26), 3779-3788. doi: 10.1016/j.vaccine.2018.05.053 |
|
2018 Journal Article The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational StudyWoodford, John, Shanks, G Dennis, Griffin, Paul, Chalon, Stephan and McCarthy, James (2018). The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. The American Journal of Tropical Medicine and Hygiene, 98 (4), 1113-1119. doi: 10.4269/ajtmh.17-0754 |
|
2018 Conference Publication A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancerYamada, M., Miller, D., Lowe, M., Rowe, C., Wood, D., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J., Brandt, G., Griffin, P., Spleman, L. and Prow, T. (2018). A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer. International Investigative Dermatology (IID) Meeting, Orlando, FL, United States, 16-19 May 2018. New York, United States: Elsevier. |
